CLL cell lines used in this study
| Name . | Ig produced . | IGHV (CDR3 subset) . |
|---|---|---|
| I83 | IgMλ | IGHV3-30M |
| HG3 | IgMλ | IGHV1-2UM |
| Wa | IgMκ | IGHV3-30.3UM (subset 32) |
| CII | IgMλ | IGHV1-69UM (subset 5) |
| 232B4 | IgGκ | IGHV3-48M |
| PGA1 | IgGκ | IGHV4-39M |
| EHEB | IgG | IGHV1-18M |
| AIII | IgMκ | IGHV4-59 |
| rIGHV3–21* | IgMλ | IGHV3-21M (subset 2) |
| Name . | Ig produced . | IGHV (CDR3 subset) . |
|---|---|---|
| I83 | IgMλ | IGHV3-30M |
| HG3 | IgMλ | IGHV1-2UM |
| Wa | IgMκ | IGHV3-30.3UM (subset 32) |
| CII | IgMλ | IGHV1-69UM (subset 5) |
| 232B4 | IgGκ | IGHV3-48M |
| PGA1 | IgGκ | IGHV4-39M |
| EHEB | IgG | IGHV1-18M |
| AIII | IgMκ | IGHV4-59 |
| rIGHV3–21* | IgMλ | IGHV3-21M (subset 2) |
Additional details and references to cell lines are given in Table S1.
M indicates mutated; UM, unmutated.
Recombinant CLL Ab produced in CHO cells (for details, see Document S1).